Best Available Treatment clinical trials

A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

This study is testing a new medicine, INCA033989, against standard treatments for essential thrombocythemia (ET). It's for people with a specific gene change (CALR mutation) who have already tried other ET medicines. The aim is to see if the new medicine works better.